Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Cancer Survival Analysis01:21

Cancer Survival Analysis

472
Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
472
lncRNA - Long Non-coding RNAs02:39

lncRNA - Long Non-coding RNAs

9.0K
In humans, more than 80% of the genome gets transcribed. However, only around 2% of the genome codes for proteins. The remaining part produces non-coding RNAs which includes ribosomal RNAs, transfer RNAs, telomerase RNAs, and regulatory RNAs, among other types. A large number of regulatory non-coding RNAs have been classified into two groups depending upon their length – small non-coding RNAs, such as microRNA, which are less than 200 nucleotides in length, and long non-coding RNA...
9.0K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

End-of-life management and causes of death in ALK-positive non-small cell lung cancer in France: a multicentric analysis.

Translational lung cancer research·2026
Same author

Molecular Profiling of Urothelial Bladder Cancer: Bridging Tumor Biology and Clinical Decision-making.

European urology oncology·2026
Same author

Prognostic stratification in resected pulmonary neuroendocrine carcinomas: Analysis of the French database EPITHOR.

Surgical oncology·2026
Same author

TLR7 induces autophagy in non-small cell lung cancer tumor cells and influences anti-tumors responses in patients.

Translational lung cancer research·2026
Same author

Pulmonary nodules in a histoplasmosis-endemic area: Diagnostic challenges and lessons from a case series.

Respiratory medicine and research·2026
Same author

Integrative and interactive genomic analyses guiding personalized combined therapy improve clinical benefit in metastatic patients: A monocentric real-life experience.

Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie·2026

Related Experiment Video

Updated: Sep 29, 2025

Competing-Risk Nomogram for Predicting Cancer-Specific Survival in Multiple Primary Colorectal Cancer Patients after Surgery
06:46

Competing-Risk Nomogram for Predicting Cancer-Specific Survival in Multiple Primary Colorectal Cancer Patients after Surgery

Published on: September 27, 2024

400

Updated Prognostic Factors in Localized NSCLC.

Simon Garinet1,2, Pascal Wang3, Audrey Mansuet-Lupo4

  • 1Pharmacogenomics and Molecular Oncology Unit, Biochemistry Department, Assistance Publique-Hopitaux de Paris, Hôpital Européen Georges Pompidou, 75015 Paris, France.

Cancers
|March 25, 2022
PubMed
Summary

Identifying prognostic biomarkers is crucial for selecting non-small cell lung cancer (NSCLC) patients who will benefit from adjuvant therapies after surgery. This improves survival outcomes and personalizes treatment strategies.

Keywords:
adjuvant chemotherapyprognosisresected NSCLC

More Related Videos

Comparison of Predictive Performance of Three Lymph Node Staging Systems in Colorectal Signet Ring Cell Carcinoma Based on Machine Learning Model
07:13

Comparison of Predictive Performance of Three Lymph Node Staging Systems in Colorectal Signet Ring Cell Carcinoma Based on Machine Learning Model

Published on: April 18, 2025

218
Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer
07:59

Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer

Published on: September 8, 2023

1.3K

Related Experiment Videos

Last Updated: Sep 29, 2025

Competing-Risk Nomogram for Predicting Cancer-Specific Survival in Multiple Primary Colorectal Cancer Patients after Surgery
06:46

Competing-Risk Nomogram for Predicting Cancer-Specific Survival in Multiple Primary Colorectal Cancer Patients after Surgery

Published on: September 27, 2024

400
Comparison of Predictive Performance of Three Lymph Node Staging Systems in Colorectal Signet Ring Cell Carcinoma Based on Machine Learning Model
07:13

Comparison of Predictive Performance of Three Lymph Node Staging Systems in Colorectal Signet Ring Cell Carcinoma Based on Machine Learning Model

Published on: April 18, 2025

218
Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer
07:59

Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer

Published on: September 8, 2023

1.3K

Area of Science:

  • Oncology
  • Translational Medicine
  • Biomarker Discovery

Background:

  • Non-small cell lung cancer (NSCLC) is a leading cause of cancer mortality globally, with surgery as a primary treatment for localized disease.
  • Current adjuvant chemotherapy (ACT) offers limited survival benefits (5-year survival < 7%) for NSCLC patients.
  • Tumor stage (TNM classification) is insufficient for predicting recurrence risk, as over 25% of early-stage (IA/B) patients relapse.

Purpose of the Study:

  • To review validated and emerging biomarkers for stratifying resected NSCLC patients.
  • To guide the selection of patients who may benefit from adjuvant targeted therapies and immunotherapies.
  • To address the need for improved patient selection to optimize adjuvant treatment strategies.

Main Methods:

  • Comprehensive literature review of clinical, pathological, and molecular biomarkers.
  • Analysis of current validated biomarkers influencing outcomes in resected NSCLC.
  • Evaluation of molecular biomarkers under investigation for adjuvant therapy selection.

Main Results:

  • Validated clinical, pathological, and molecular biomarkers currently influence outcomes in resected NSCLC.
  • Emerging molecular biomarkers show potential for daily practice to guide ACT decisions.
  • Adjuvant targeted therapies are approved for EGFR-mutated NSCLC, with ongoing trials for other agents.

Conclusions:

  • There is a critical need for improved prognostic and theranostic markers to personalize adjuvant therapy selection in resected NSCLC.
  • Better patient stratification can optimize treatment efficacy, minimize side effects, and reduce healthcare costs.
  • Future research should focus on validating novel biomarkers for routine clinical application in NSCLC management.